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Table 1. Basic characteristics of the models and methodology used by the World Health 
Organization and the Global Burden of Disease study to obtain country specific and 
global TB mortality estimates. 
 
WHO GBD 
Overall model strategy 
Several internally consistent 
models 
Cause Of Death Ensemble 
approach (mix effects 
regression) 
Data sources included in models: 
Vital registration data Yes Yes 
Mortality surveillance data  Yes Yes 
Verbal autopsies No Yes 
Prevalence surveys Yes No 
Specific case fatality ratios Yes No 
Data stratified by HIV status Yes Yes 
Data stratified by age Yes (two groups) Yes 
Data stratified by sex Yes (adults) Yes 
Population  UN estimates GBD estimates 
Methods published? Yes Yes 
Uncertainty incorporated Yes Yes 
  






























































Table 2. Global absolute differences in TB attributable number of deaths during 2015, 
as estimated by the World Health Organization and the Global Burden of Disease 
Study, by sex, age group and HIV status. 













HIV+TB only 211604 389042 177438 -84% 46% 
TB only 1111312 1379440 268128 -24% 19% 
Total TB 1322916 1768482 445566 -34% 25% 
Adults 
HIV+TB only 177567 348026 170458 -96% 49% 
TB only 1075691 1210620 134929 -13% 11% 
Total TB 1253257 1558645 305388 -24% 20% 
Children 
HIV+TB only 34037 41016 6979 -21% 17% 
TB only 35621 168821 133199 -374% 79% 
Total TB 69659 209837 140178 -201% 67% 
Female* 
HIV+TB only 78110 143496 65386 -84% 45% 
TB only 367764 352488 15276 4% -4% 
Total TB 445874 495984 50110 -11% 10% 
Male* 
HIV+TB only 99457 204471 105013 -106% 51% 
TB only 707927 858132 150205 -21% 18% 
Total TB 807383 1062603 255219 -32% 24% 
 
*Sex stratification was only possible among adults (WHO does not provide sex 
stratification in people <15 years of age). 
 

































































Figure 1. Ranking by (A) magnitude of absolute difference between World Health Organization and Global 
Burden of Disease study estimates and (B) the ratio of the absolute difference and number of reported 
deaths by country.  
 
 

































































(A) Absolute differences (log scale) and (B) Standardized differences in World Health Organization’s and 
Global Burden of Disease study’s number of TB deaths estimates by country (year 2015).  
 
 

































































Figure 3. Correlation between World Health Organization’s and Global Burden of Disease study’s estimated 
number of TB deaths by UN world region. 
*number of deaths in log scale.  
 
 

































































Figure 4. Ranking by magnitude of standardized difference (re-scaled) of World Health Organization and 
Global Burden of Disease Study TB mortality estimates among a) all tuberculosis deaths (all ages, all types) 
b) childhood TB deaths (all types) c) HIV-TB deaths (all ages) by country. 
* When both WHO and GBD study estimated fewer than 5 deaths for a given subgroup, we removed those 
countries from the rankings of standardized difference.  
 
 

































































Figure 6. Standardized difference in mortality estimates by World Health Organization and Global Burden of 
Disease study by having had a nationwide prevalence survey in the country (2009-2015) (1) or not (0). 
* Boxes represent 25th-75th percentile, horizontal line represents median value.  
 
 

































































Figure 5. Ecological association of standardized difference in mortality estimates by the World Health 
Organization and Institute for Health Metrics and Evaluation with a) HIV prevalence b) MDR prevalence 
(WHO) c) Estimated Case Detection Rate by WHO d) Estimated case detection rate (based on GBD incidence 
data) 
* Line represents linear regression line.  
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The World Health Organization (WHO) and the Global Burden of Disease (GBD) study 
at Institute for Health Metrics and Evaluation (IHME) periodically provide global 
estimates of tuberculosis mortality. We compared the 2015 WHO and GBD 
tuberculosis mortality estimates and explored which factors might drive thedifferences. 
 
Methods 
We extracted the number of estimated tuberculosis-attributable deaths, disaggregated 
by age, HIV status, sex, and country from publicly available WHO and GBD datasets 
for the year 2015. We “standardized” differences between sources by adjusting each 
country’s difference in absolute number of deaths by the average number of deaths 
estimated by both sources. 
 
Results 
For 195 countries with estimates from both institutions, WHO estimated 1,768,482 
deaths attributable to TB, whereas GBD estimated 1,322,916 deaths, a difference of 
445,567 deaths or 29% of the average of the two estimates. The countries with the 
largest absolute differences in deaths were Nigeria (216,621), Bangladesh (49,863) 
and Tanzania (38,272). The standardized difference was not associated with HIV 
prevalence, prevalence of multidrug resistance or global region, but did show s 
correlation with the case detection rate as estimated by WHO (r=-0.37, 95%CI: -048; -
0.24) or, inversely, with case detection rate based on GBD data (r=0.42, 95%CI: 0.31; 
0.54). Countries with a recent national prevalence survey had higher standardized 
differences (higher estimates by WHO) than those without (p=0.006). After exclusion of 
countries with recent prevalence surveys the overall correlation between both 
estimates was r=0.991. 


































































A few countries account for the large global discrepancy in TB mortality estimates. The 
differences are due to the methodological approaches used by WHO and GBD. The 
use and interpretation of prevalence survey data and case detection rates seem to play 
a role in the observed differences.  
 
Keywords: tuberculosis; mortality; death; burden; estimates; epidemiology; Global 
Burden of Disease, World Health Organization;  
  


































































• Given the contribution of tuberculosis as a global cause of death, being the 
main infectious cause of death in several settings, the precise assessment of its 
burden is critical to prioritize health interventions at national level and globally.  
• We identify a list of countries for which tuberculosis mortality figures should be 
carefully reviewed. Our findings suggest that the methodology and different 
data sources used by WHO and GBD might be driving the differences in TB 
mortality estimates.  
• A global difference of nearly 450,000 deaths (and country differences higher 
than 10,000 deaths) hinders the assessment of the End-TB programmatic 
targets in some countries.  
• These findings urge both institutions to take a closer look at the modelling 
approaches where differences are largest, in order to understand the true 
burden of TB in those settings. These results also call for investment in the 
development and / or improvement of high quality vital registration systems 
around the world. 
 
  

































































Mycobacterium tuberculosis is the single infectious agent that caused the largest 
number of deaths in 2016. It has been a major cause of death in previous centuries 
and potentially, in the history of humankind.1,2 In the pre-chemotherapy era, the 10-year 
case fatality of smear-positive tuberculosis (TB) ranged from 53% to 86%, with 3 years 
duration on average from onset of disease to death.3 Since a considerable proportion 
of TB cases are not diagnosed and many of the deaths among diagnosed patients are 
not accurately assigned,4 global mortality figures are  estimates derived from 
mathematical and statistical models. The World Health Organization (WHO) estimated 
that in 2015, there were 10.4 million new cases and 1.7 million deaths attributable to 
TB.2 This alarming mortality burden attributed to TB in 2015 represents a 20% increase 
from 2014, driven not by a true upward trend, but based on newly available data from 
notifying countries and refinement of the modelling approach.2,5 
Over the last 20 years, the Institute of Health Metrics and Evaluation (IHME) at 
University of Washington in Seattle, has developed a methodology to quantify the 
burden of multiple communicable and non-communicable diseases, injuries and risk 
factors, with the underlying objective of guiding international and local policy making.6 
The Global Burden of Disease (GBD) study, a broad international collaborative effort by 
IHME, periodically provides estimates on different key indicators of burden of disease 
assessment, including those related to TB. A comparison of the authoritative TB 
estimates by WHO and GBD for 2013 showed that global mortality figures were 
reasonably similar (WHO: 1.3 million deaths and GBD: 1.4 million deaths), although 
important differences existed at national and regional levels.7,8 Interestingly, global 
estimates for TB deaths among HIV-uninfected people were considerably different: 0.9 
vs 1.3 million as estimated by WHO and GBD, respectively. The available information 
for the year 2015 shows bigger discrepancies. Recently released estimates by GBD for 
2015 amount to 1.3 million deaths (1.1 among HIV negative cases, range 0.9-1.4),9,10 
































































which is significantly different to 1.8 million (1.4 among HIV negative cases, range 1.2-
1.6) estimated by WHO for the same year.  
TB mortality estimates vary due to the different underlying assumptions used in the two 
approaches. Although neither institution used to release much detail on their exact 
methods, since 2015 the WHO has included a specific appendix in their annual Global 
Tuberculosis Report in which the main assumptions underlying their TB mortality 
models are specified.2 General information on the GBD approach for mortality has 
been published by GBD,9,11 and TB-specific methodology for their 2015 estimates has 
recently been released.10 
Burden of disease assessment is critical to prioritize health policy and planning at 
country level and globally. We sought to provide a detailed comparison of the 2015 
WHO and GBD TB mortality estimates and explore which factors might drive the 
observed differences at national, regional and global level. 
 
METHODS 
Data sources and management 
Data from the Global Burden of Disease 2015, GBD2015 iteration, were downloaded in 
December 2016 using the data health tool, available at http://ghdx.healthdata.org/gbd-
results-tool. Variables included: number of deaths and mortality rate, disaggregated by 
age, HIV status, sex, and country. Data from WHO were downloaded from 
http://www.who.int/tb/country/data/download/en/ (global TB burden, case notifications 
and TB treatment outcomes datasets) in December 2016. Since WHO did not include 
data stratified by sex and age, additional disaggregated data by these two variables 
were requested and obtained from the Global TB Department. 
































































A master dataset containing raw data from both sources was created and is freely 
available online for the sake of transparency and reproducibility. All source code is also 
freely available at www.github.com/joebrew/tb_mortality. 
Data analysis 
We described absolute differences in TB mortality estimates by both methods by age 
(adults vs children), sex, HIV status and global region. In addition, we described the 
differences in TB mortality estimates by both methods as the ratio between the 
estimated and reported numbers of deaths. Since the absolute difference in deaths 
might be driven by country’s TB burden, we standardized the differences in mortality 
estimates by adjusting each country’s difference in absolute number of deaths by the 
average number of deaths estimated by WHO and GBD using the formulae: (a-
b)/((a+b)/2), where a and b are the numbers of deaths estimated by WHO and GBD 
respectively. This standardization yielded a metric (standardized difference) that takes 
into account the TB burden in the country. Since its scale cannot easily be interpreted, 
for plotting country rankings we rescaled this metric to a -100 to +100 scale, using the 
relative difference as a proportion of the maximum value obtained, yielding a positive 
score for a given country when WHO estimates were higher than GBD’s and vice 
versa. Therefore, a score of +100 or -100 would represent the maximum difference in 
TB deaths observed between WHO and GBD relative to the average number of 
estimated deaths. When both estimated fewer than 5 deaths for a given subgroup, we 
removed those countries from the rankings of standardized difference. In a sensitivity 
analysis we explored whether the standardization of the absolute difference in number 
of TB deaths (WHO-GBD) by reported number TB deaths yielded different results with 
regards to potential drivers of the difference (online supplementary material). 
Methods used by WHO and GBD to estimate TB mortality 
The methods by which WHO estimated TB mortality in 2015 have been published in 
the 2016 Global TB report, released in October 2016.2 A comprehensive explanation of 
































































these methods is beyond the scope of this analysis. Briefly, the main data sources 
included direct measurements of mortality from vital registration systems or mortality 
surveys (145 countries) and indirect estimates obtained through estimated TB 
incidence and estimated case fatality rates (CFRs) among untreated patients. Mortality 
among HIV positive individuals was estimated using CFRs derived from previously 
published HIV-specific CFR data and other assumptions, including being on TB or HIV 
(antiretroviral) treatment.2,12–14 
The methodology used in the GBD study to estimate TB mortality has recently been 
released.10.9  TB mortality has been estimated in a different fashion for HIV negative 
and positive individuals. For HIV negative individuals, the GBD study uses data 
sources from vital registration data, verbal autopsies and mortality surveillance data. 
These data sources were then modelled using different modelling strategies (mixed 
effects models and spatiotemporal Gaussian process regression models), as part of 
the cause of death ensemble modelling (CODEm) strategy.10 Mortality among HIV-
positive individuals was estimated based on the calculation of on the fraction of TB/HIV 
deaths among all TB deaths using data from countries with high quality vital registration 
data. It entails estimating the proportion of HIV positive TB cases among all TB 
patients, as well as the relative risks of TB death among patients TB and HIV. Further 
details are given in the methods section as well as in the appendix 1 of the article on 
global burden of TB from GBD2015.10 A general comparison of the different 
approaches by WHO and GBD is given in table 1. 
In order to explore what drivers could account for the observed differences, we 
analysed the association of the per-country standardized difference metric with 
potentially explanatory variables including case detection rate (CDR) as estimated by 
WHO, calculated CDR based on GBD data using incident cases estimated by IHME 
divided by the reported cases by countries, HIV burden using reported prevalence of 
HIV among new TB cases, prevalence of multidrug resistance TB among new cases as 
































































reported by WHO, availability of recent nationwide prevalence survey results, and 
WHO region. Correlation coefficients were calculated and regression lines were plotted 
for each variable. Since all countries with available WHO and GBD estimates were 
included, no random error was taken into account except for the correlations; neither 
did we consider reported uncertainty for the per-country or aggregated estimates. 
 
RESULTS 
Mortality estimates for 2015 from both WHO and GBD were available for 195 countries. 
WHO estimated TB mortality for 23 additional countries, which accounted for 238 
deaths in total. Among those 195 countries with estimates from both institutions, WHO 
estimated 1,768,482 deaths attributable to TB, whereas GBD estimated 1,322,916 
deaths, resulting in a difference of 445,567 deaths (25.2% reduced mortality if taking 
WHO as the reference, or 33.7% increased mortality if GBD is the reference). This 
difference in TB mortality was higher in people living with HIV (211,604 by GBD vs 
389,042 by WHO), where WHO estimated 84% more deaths attributable to TB than did 
GBD. The relative difference in number of deaths was especially high for children (<15 
years of age), where WHO estimated three times more deaths than did GBD (209,837 
vs 69,659 number of deaths by WHO and GBD respectively). In both estimates there 
were almost twice as many deaths estimated among adult men than among women 
with the smallest relative differences among HIV negative women (table 2). 
For 86 (44.1%) of 195 countries WHO estimated a higher number of TB deaths than 
did GBD. The 10 countries with the largest absolute differences in total number of TB 
deaths were (by decreasing magnitude of the difference): Nigeria (216,621 deaths 
difference), Bangladesh (49,863), Tanzania (38,272), South Africa (29,108), 
Mozambique (28,909), Indonesia (26,121), Democratic Republic of Congo (26,010), 
India (20,696), North Korea (13,218), and Angola (9,910). The top-10 countries in 
which GBD estimated higher number of deaths than WHO were: Ethiopia (22,650), 
































































China (13,538), Zimbabwe (11,082), Philippines (9,436), Nepal (5,477), Uganda 
(5,081), Burkina Faso (4,837), Niger (3,758), Viet Nam (3,252), and Senegal (3,147)  
(figure 1A). Figure 2A shows how the largest differences in terms of absolute number 
of deaths were concentrated in few countries, with Nigeria alone accounting for almost 
half of the difference in estimated global TB mortality between the two methods. In fact, 
the correlation of TB mortality estimates between both methods was very good for most 
countries and regions (figure 3), with an overall correlation coefficient of 0.92. 
After standardization, the countries with highest difference in estimates were 
Azerbaijan (-100.0), Nigeria (99.9) and Marshall Islands (91.2). The differences in 
absolute number of childhood TB deaths estimates were largest in India (59,508), 
Nigeria (32,004) and Indonesia (12,752). After standardization, the magnitude of this 
difference was greatest in North Korea (100.0), Bangladesh (99.4) and Timor Leste 
(99.1). Regarding differences in TB-HIV deaths (all ages), Nigeria (52,805), South 
Africa (29,594) and Indonesia (19,480) were the countries with highest differences in 
absolute numbers, and Turkmenistan (-100), Chile (-82.7) and Argentina (-73.7) 
showed the largest standardized differences (figure 4 and supplementary table 1). In 
nine countries, the difference between WHO and GBD estimates of number of deaths 
was more than 10 times than the number reported by the country: Libya (117 times 
higher), Nigeria (43), Iceland (23), Congo (22), Afghanistan (16), Eritrea (13), Timor-
Leste (11) and Tanzania (11) (figure 1B). In the online supplementary material, the 
interactive map shows all indicators of this descriptive analysis by country. 
After standardization of the absolute differences in mortality estimates for the WHO-
GBD averaged estimate we found no associations with the following potential drivers of 
this difference: reported HIV prevalence among new TB cases (r = -0.001, 95% CI: -
0.16; 0.15) and multidrug/rifampicin resistance prevalence (r= 0.06, 95% CI: -0.09; 
0.20). There was an association with case detection rate (as estimated by WHO), (r = -
0.37, 95% CI: -0.49; -0.24) which showed an inverse association when using CDR 
































































based on GBD-estimated number of incident cases (r= 0.44, 95% CI: 0.31; 0.54) 
(figure 5) and with case fatality rate as estimated by WHO (r= 0.37, 95% CI: -0.49; -
.24). Countries that conducted a national prevalence survey between 2009 and 2015 
had a higher median standardized difference than those that did not (0.330 vs -0.104, 
respectively) (figure 6). In other words, in those countries for which national 
prevalence survey data were available, WHO tended to estimate higher numbers of TB 
deaths (p=0.006). For the 19 countries that had national prevalence surveys, WHO 
estimated rather low CDRs, being below 75% for all except two countries (China and 
Rwanda). Removing the 19 countries with a prevalence survey, the correlation 
between WHO and GBD number of deaths estimates improved from r=0.92 to r=0.99. 
Standardization of the absolute difference in number of TB deaths (WHO-GBD) by 
reported number of deaths yielded associations with potential drivers of the mortality 
difference of similar direction and magnitude (Supplementary figure 1). There was 
again a negative correlation between standardized difference and WHO-estimated 
CDR (r=-0.32, 95%CI -0.45;-0.18); the positive correlation with CDR based on GBD-
estimated number of deaths disappeared (r= 0.09, 95%CI -0.06; 0.24). Also countries 
with prevalence surveys had a higher mean standardized difference (mean 3.5) than 
those without (0.88) (Supplementary figure 2). 
 
DISCUSSION 
Despite using different approaches, the latest estimates of TB mortality by WHO and 
IHME are similar for most countries in the world. The global TB mortality estimates are 
nonetheless quite different due to large differences for a small number of countries. 
Twelve countries showed a difference in their TB mortality of more than 10,000 deaths: 
Nigeria, Bangladesh, Tanzania, South Africa, Mozambique, Indonesia, Democratic 
Republic of Congo, India, North Korea, Ethiopia, China, Zimbabwe. Only for the latter 
three countries, IHME estimated higher numbers of deaths than did WHO. With the 
































































possible exception of some countries with a large TB burden, such as China or India, 
these absolute differences in estimated number of deaths likely reflect relevant effects 
of differences in modelling methods and data sources used. This is further supported 
by absolute differences in estimated numbers of deaths being >10 times larger than the 
reported numbers of TB deaths for several of these countries. The absolute differences 
in TB deaths found among HIV positive cases or children are also concentrated in 
similar countries as for all TB with some exceptions. Nonetheless the standardized 
differences are different, reflecting the specific HIV burden and demographic 
characteristics of the countries. In addition, the lack of reliable data sources for children 
adds uncertainly to paediatric TB death estimates.15 
HIV prevalence among new TB cases, as a proxy for HIV/TB burden in the country and 
prevalence of MDR-TB did not seem to be determinant factors for the differences 
observed. We did find an association with the case detection rate as estimated by 
WHO or GBD: the lower the CDR as estimated by WHO, the larger the standardized 
difference between WHO and GBD estimates. This association also existed, but in 
opposite direction, for CDR using GBD’s-estimated numbers of cases. The association 
with CFR as estimated by WHO is likely due to the association with CDR. In addition, 
differences in the estimation of TB deaths seemed to be driven by the availability of 
national prevalence survey data. When removing the countries with recent prevalence 
survey data, the correlation of WHO and GBD estimates came close to 100%. 
Several differences in methodology used by WHO and GBD may account for the 
differences in mortality estimates. For countries with poor vital registration and disease 
reporting systems, any method for estimating TB mortality has to deal with two 
information gaps that cannot be directly observed: the number of individuals with TB 
disease who are never diagnosed and/or reported, and the death rate due to TB 
among these individuals. The former is reflected in the CDR that is generally expressed 
as the ratio of the number of TB patients reported and the number of estimated incident 
































































TB cases over a given period. The latter is referred to as the case fatality rate (CFR). 
Both approaches (from GBD and WHO) have different ways of taking these two 
variables into account. 
The WHO uses three main strategies to account for the undiagnosed cases: for high 
income countries, notifications are adjusted by a standard factor, and for low- and 
middle-income countries, either data from prevalence surveys are used or notification 
data are combined with expert opinion. Nine other countries use data from capture-
recapture analyses or from inventory studies. For 74 countries, expert opinion was 
used. This approach, which is not based on observational data, has clear limitations 
and introduces a high degree of uncertainty in the estimates. For 19 countries the CDR 
was based on findings from national prevalence surveys (and for India from one 
regional prevalence survey), which, according to WHO, represent 62% of all TB 
incidence.2 Prevalence surveys have generally lowered the case detection rate 
estimated by WHO compared to the previous estimate.2 In fact this happened for 
Tanzania and Nigeria, two of the three countries with highest absolute differences. The 
association of low CDR with higher mortality estimated by WHO might thus be driven 
by the countries that had a prevalence survey. 
The use of data from prevalence surveys also has implications for the way CFRs are 
applied to obtain estimated numbers of deaths. Half or more of the patients detected in 
prevalence surveys are asymptomatic2, and their true CFR may be lower than that for 
patients with TB symptoms. For Nigeria and Tanzania, which account for 57% of the 
total global difference in TB mortality estimates, the CDR estimate was lowered as 
result of their prevalence surveys. If TB mortality is lower among asymptomatic than 
among symptomatic cases detected through prevalence surveys, WHO might be 
overestimating true TB mortality in those countries. In addition, in countries without 
reliable vital registration systems, case fatality rates are derived from the product of TB 
incidence and CFR (for treated and untreated). However, no adjustment is made for 
































































setting specific CFR, which we believe might vary depending on the specific country 
health profile. 
Estimating TB deaths among HIV patients is complex since people living with HIV who 
die from TB are registered as HIV deaths, and the intermediate causes are not always 
registered. For countries with VR systems or mortality surveys, GBD study uses 
different algorithms that help to identify garbage codes from the death certificates 
(assigned codes that are not real causes of death) and redistribute to the most 
plausible causes. This process adds certain uncertainty to data even in countries with 
good quality VR systems. In addition, GBD uses verbal autopsy data as one of the 
sources for estimating TB mortality. Verbal autopsies provide poor quality estimates 
and have limited sensitivity and specificity for TB against clinical diagnosis or autopsy 
findings, especially in high HIV infection prevalence settings.4,16–18 Clinical (premortem) 
diagnosis itself has shown a high degree of discrepancy with autopsy findings for TB 
diagnosis.19–21 If clinicians fail to diagnose TB premortem, it is likely that verbal autopsy 
data is even less accurate. Indeed, two recent studies comparing verbal autopsy and 
classical autopsy findings for TB diagnosis showed that verbal autopsies over- or 
underestimated the true burden of TB in two sub-Saharan settings.17,18 The decision to 
not include verbal autopsy data from countries with HIV prevalence above 5% will 
minimize this source of error, but further studies are needed to validate verbal autopsy 
findings (against autopsy findings) and see whether its systematic use plays a role in 
underestimating or overestimating TB mortality. 
This analysis has several limitations. The standardisation used for analysing potential 
drivers of the differences in mortality estimates is based on the adjustment of those 
estimates by the average number of deaths estimated by both institutions, as a proxy 
of the true country mortality burden. However, this standardization approach assumes 
both approaches are equidistant from the true number of TB deaths, which may not be 
the case. Alternative standardisation by adjustment for reported number of deaths 
































































showed less pronounced associations with GBD-estimated CDR and use by WHO of 
national prevalence survey data. This standardization may also have introduced bias 
because the departure of estimated number of deaths from reported number of deaths 
strongly depends on the CDR and this would have not been taken into account. 
Secondly, although in recent years more detail has been provided on the modelling 
approaches and data sources used, we believe that neither WHO’s nor GBD’s 
estimates are fully reproducible using publicly accessible data. This adds a layer of 
uncertainty on how figures are obtained. Public availability of some input data sources 
might conflict with confidentiality agreements established by countries or institutions. In 
addition, GBD and WHO updated estimates supersede the previous ones for any 
particular year, hindering a comprehensive understanding and retrospective analysis of 
a specific year’s estimates. Lastly, we have not been able to compare of mortality 
estimates due to MDR-TB or XDR-TB (not provided by GBD), which is a growing 
problem. We believe that a specific methodology to estimate mortality among this 
subgroup needs to be incorporated. 
The fact that two independent institutions make an important effort to come up with 
global TB burden indicators must be welcomed and appreciated. We consider that it is 
beneficial that there is not a single institution claiming full authority on TB or any 
disease estimates, which allows to further discuss methods, and ultimately improve 
estimates for relevant public health indicators. Nonetheless, there is a need to provide 
a clearer picture about the magnitude of TB mortality for some specific countries, as 
well as to analyse the reasons for the estimation differences between WHO and GBD. 
There may be elements in both institutions’ methodologies that may result in over- or 
underestimating TB mortality. A global difference of nearly 450,000 deaths (and 
country differences higher than 10,000 deaths) makes it difficult to assess progress on 
control efforts directed at reducing mortality in some settings. We recommend both 
GBD and WHO to take a closer look at the modelling approaches for the countries with 
































































highest absolute differences in TB mortality estimates by both institutions, as well as for 
those countries which highest differences relative to the size of their reported mortality. 
Likewise, there is an urgent need to invest in the creation and / or improvement of high 
quality vital registration systems, which are lacking in many high TB burden countries. 
Lastly, new tools to diagnose TB as cause of death need to be implemented. Since full 
post-mortem examination is rarely performed in countries lacking vital registration 
systems, alternative approaches for TB assessment at death, such as minimally 
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Tables and Figures 
Table 1. Basic characteristics of the models and methodology used by the World Health 
Organization and Institute of Health Metrics to obtain country specific and global TB 
mortality estimates. 
Table 2. Global absolute differences in TB attributable number of deaths during 2015, 
as estimated by the World Health Organization and Institute of Health Metrics and 
Evaluation, by sex and age group. 
Figure 1. Ranking by (A) magnitude of absolute difference between World Health 
Organization and Global Burden of Disease study estimates and (B) the ratio of the 
absolute difference and number of reported deaths by country. 
Figure 2. (A) Absolute differences (log scale) and (B) Standardized differences in 
World Health Organization’s and Global Burden of Disease study’s number of TB 
deaths estimates by country (year 2015). 
Figure 3. Correlation between World Health Organization’s and Global Burden of 
Disease study’s estimated number of TB deaths by UN world region. 
*number of deaths in log scale. 
Figure 4. Ranking by magnitude of standardized difference (re-scaled) of World Health 
Organization and Global Burden of Disease Study TB mortality estimates among a) all 
tuberculosis deaths (all ages, all types) b) childhood TB deaths (all types) c) HIV-TB 
deaths (all ages) by country. 
* When both WHO and GBD study estimated fewer than 5 deaths for a given subgroup, we 
removed those countries from the rankings of standardized difference. 
Figure 5. Ecological association of standardized difference in mortality estimates by the 
World Health Organization and Institute for Health Metrics and Evaluation with a) HIV 
prevalence b) MDR prevalence (WHO) c) Estimated Case Detection Rate by WHO d) 
Estimated case detection rate (based on GBD incidence data) 
* Line represents linear regression line. 
Figure 6. Standardized difference in mortality estimates by World Health Organization 
and Global Burden of Disease study by having had a nationwide prevalence survey in 
the country (2009-2015) (1) or not (0). 




 percentile, horizontal line represents median value. 
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